argenx (ARGX) announces FDA approval of VYVGART Hytrulo Apr 10, 2025 06:02PM
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Apr 10, 2025 05:47PM
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies Nov 20, 2024 01:00AM
Zai Lab Limited (ZLAB) and argenx (ARGX) Announce Approval of VYVGART Hytrulo Nov 11, 2024 07:31AM
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China Nov 11, 2024 07:30AM
View Older Stories

Nov 5, 2024 01:00AM argenx to Participate at Upcoming Investor Conferences
Oct 15, 2024 01:00AM argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Fo
Sep 19, 2024 01:00AM argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
Jul 16, 2024 12:15AM Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Jun 21, 2024 04:52PM argenx (ARGX) Announces FDA Approval of VYVGART Hytrulo
Jun 21, 2024 04:50PM argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
Jun 17, 2024 01:00AM argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
Apr 16, 2024 01:00AM argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Mar 27, 2024 02:00AM argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
Feb 20, 2024 03:10AM argenx (ARGX) Announces FDA Acceptance of sBLA and Priority Review for VYVGART Hytrulo
Feb 20, 2024 01:00AM argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Jan 18, 2024 05:08AM argenx (ARGX) Announces Approval of VYVDURA in Japan
Jan 18, 2024 01:00AM argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
Jan 8, 2024 05:32AM argenx (ARGX) Highlights 2024 Strategic Priorities
Jan 8, 2024 01:00AM argenx Highlights 2024 Strategic Priorities
Dec 20, 2023 03:55AM argenx (ARGX) Reports ADDRESS Study of Efgartigimod SC Did Not Achieve Statistical Significance
Dec 20, 2023 01:00AM argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
Sep 21, 2023 01:00AM argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
Jun 30, 2023 09:39AM argenx (ARGX) and Zai Lab (ZLAB) Announce FDA Approval of VYVGART
Jun 30, 2023 09:39AM argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
Jun 30, 2023 09:25AM Zai Lab Limited (ZLAB) and argenx Announce Approval of VYVGART for Generalized Myasthenia Gravis in China
Jun 30, 2023 09:22AM Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
Jun 20, 2023 06:13PM argenx (ARGX) Announces FDA Approval of VYVGART Hytrulo Injection
Jun 20, 2023 06:12PM argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
Jun 20, 2023 01:00AM argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
May 2, 2023 01:00AM argenx to Present at BofA Securities 2023 Health Care Conference
Apr 27, 2023 01:00AM argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
Apr 18, 2023 01:00AM argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
Apr 17, 2023 05:32AM Genmab A/S (GMAB) and argenx (ARGX) Partner to Advance Antibody Therapies in Immunology and Oncology
Apr 17, 2023 02:00AM argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Apr 17, 2023 02:00AM Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Mar 17, 2023 04:01PM argenx Announces Annual General Meeting of Shareholders on May 2, 2023
Mar 2, 2023 05:45AM argenx (ARGX) Announces COO Transition Plan
Mar 2, 2023 01:00AM argenx Announces Planned Transition of Chief Operating Officer
Mar 2, 2023 01:00AM argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
Feb 27, 2023 04:01PM argenx (ARGX) Appoints Steve Krognes to its Board
Feb 27, 2023 04:01PM argenx Appoints Steve Krognes to Board of Directors
Feb 27, 2023 01:00AM argenx to Present at Upcoming Investor Conferences
Feb 23, 2023 01:00AM argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
Jan 16, 2023 01:30PM argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
Jan 9, 2023 04:53AM argenx (ARGX) Reports Prelim FY22 VYVGART Sales of $402M, Highlights 2023 Strategic Priorities
Jan 9, 2023 01:00AM argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
Jan 3, 2023 01:00AM argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
Dec 12, 2022 04:02PM argenx (ARGX) names Ana Cespedes to board
Dec 12, 2022 04:01PM argenx Appoints Ana Cespedes to Board of Directors
Dec 10, 2022 11:30AM argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
Nov 30, 2022 06:20AM argenx (ARGX) to Acquire Priority Review Voucher from FDA for $102M
Nov 30, 2022 01:00AM argenx Enters Into Agreement To Acquire Priority Review Voucher
Nov 22, 2022 01:00AM argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
Nov 7, 2022 01:00AM argenx to Present at Upcoming Investor Conferences
View Older Stories